Treatment.com AI Stock Price, News & Analysis

Rocket Doctor AI Inc. (CSE: AIDR; OTC: TREIF) has successfully closed an over-subscribed non-brokered private placement, raising total gross proceeds of C$4.23 million. The offering consisted of 3,677,400 special warrants at $0.50 per warrant for C$1.84 million, and 4,792,000 units at $0.50 per unit for C$2.39 million.

Each unit includes one common share and one purchase warrant exercisable at $0.75 for 12 months. The company paid C$201,616 in finder's fees and issued 403,232 broker warrants. The funds will be used for sales and administrative expenses, software R&D, and working capital, with a focus on accelerating US expansion plans.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has announced its rebranding to Rocket Doctor AI Inc., with trading under the new ticker symbol AIDR beginning August 21, 2025. This strategic transformation follows the successful April 2025 acquisition of Rocket Doctor Inc.

The rebranding unifies the company's proprietary Global Library of Medicine (GLM) with Rocket Doctor's digital health platform, creating an integrated solution that leverages AI, large language models, and connected medical devices to improve healthcare access. The combined technology stack focuses on delivering AI-enhanced clinical and diagnostic tools, particularly targeting rural, remote, and underserved communities across North America.

The company's GLM platform has undergone over 10,000 expert medical reviews and aims to reduce administrative burden for healthcare professionals while improving patient care quality and consistency.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) reports significant growth of its Rocket Doctor platform amid Ontario's healthcare crisis. Patient visits through the platform increased 63% year-over-year, from 38,378 in 2023 to 62,648 in 2024. Since 2020, Rocket Doctor has served over 360,000 patients in Ontario.

The platform has been particularly impactful in underserved areas, with 102,000+ patients from communities under 30,000 population accessing care. Physician adoption continues to grow, with 138 Ontario doctors now on the platform, including 27 new physicians joining in the first half of 2025.

This growth comes as Ontario faces its worst year of ER closures in 2024, with 1 in 5 hospitals experiencing unplanned shutdowns, while 2.5 million Ontarians lack a family doctor as of 2023.

Treatment.com AI (CSE: TRUE, OTC: TREIF) has reported significant success with its Rocket Doctor platform's Emergency Department (ED) diversion program. At Georgian Bay General Hospital, the program has successfully managed over 3,065 patients between June 2022 and December 2024, with 97.5% handled virtually and only 1% requiring ED redirection.

The program has generated estimated savings of $1.4 million, based on average ED visit costs of $475. In Alberta, Rocket Doctor has facilitated 12,000+ patient visits in the last three months, achieving a 98% virtual resolution rate with less than 1% requiring ED visits. The platform combines smart triage, provider infrastructure, and AI-enabled care to address Canada's emergency department crisis, particularly impacting rural communities.

Treatment.com AI (OTC: TREIF) has engaged Independent Trading Group (ITG) as its market maker starting July 29, 2025. The agreement aims to maintain reasonable market conditions and enhance the liquidity of Treatment's common shares across all trading venues.

Under the agreement terms, ITG will receive CAD $5,500 monthly compensation, with an initial one-month term that automatically renews unless terminated with 30 days' notice. No performance factors, shares, or options are included in the compensation package. ITG, established in 1992, is a Toronto-based CIRO dealer-member specializing in market making and liquidity provision services.

Treatment.com AI (OTC: TREIF) has announced strategic marketing partnerships with two service providers to enhance its digital presence and investor awareness. The company has engaged 45 Degrees Inc. for a six-month digital marketing campaign at USD $180,000, with potential monthly extensions at $25,000.

Additionally, Treatment.com has partnered with Investment Publishing LLC for a one-year investor relations strategy enhancement program. As compensation, the company has issued 400,000 stock options each to both service providers' principals, exercisable at $0.45 per share for three years. The company has also granted an additional 400,000 options to arm's length consultants under the same terms.

Treatment.com AI (CSE: TRUE, OTC: TREIF) reported significant success with its Rocket Doctor platform's Emergency Department (ED) diversion program. At Georgian Bay General Hospital, the program has successfully managed over 3,065 patients between June 2022 and December 2024, with 97.5% handled virtually and only 1% requiring ED redirection.

The program has generated estimated savings of $1.4 million, based on an average cost of $475 per diverted ER visit. In Alberta, the platform has facilitated 12,000+ patient visits in the last three months, with 98% resolved virtually and less than 1% requiring ED visits. The solution combines smart triage, provider infrastructure, and AI-enabled care to address Canada's emergency department crisis, particularly impacting rural communities.

Treatment.com AI (OTC: TREIF) has announced that its subsidiary, Rocket Doctor, is partnering with EngageWell IPA to launch the Healthy Aging Program, backed by a $1 million, 5-year grant from the CVS Health Foundation. The program offers virtual health screenings for adults aged 60+ across New York City.

The initiative provides free virtual assessments for heart health, memory, cognitive function, and mental health, conducted by board-certified physicians. Participants can receive up to $45 in gift cards upon completion. The service is free for Medicaid patients and covered by insurance for Medicare patients. The program includes support from Community Health Workers who assist with telehealth connections and follow-up care coordination.

Treatment.com AI (OTC: TREIF) reports significant progress following its acquisition of Rocket Doctor, showcasing strong growth metrics and strategic achievements. Rocket Doctor's patient volume surged 112% year-over-year in Alberta, serving over 36,000 patients in 2024, while physician adoption grew by 218% from 22 to 70 active physicians.

Key developments include partnerships with Central California Alliance for Health (450,000-member managed care plan) and Melanoma Canada, plus the deployment of their Medical Education Suite at the University of Minnesota Medical School, potentially reducing exam costs by 40%. The company received recognition as Top Clinical Innovator by the American Telemedicine Association and secured positions in prestigious programs including UC Berkeley Health Engine Accelerator and AARP AgeTech Accelerator.